Albumin and multiple sclerosis

A grant from the One-University Open Access Fund at the University of Kansas was used to defray the author's publication fees in this Open Access journal. The Open Access Fund, administered by librarians from the KU, KU Law, and KUMC libraries, is made possible by contributions from the offices of KU Provost, KU Vice Chancellor for Research & Graduate Studies, and KUMC Vice Chancellor for Research. For more information about the Open Access Fund, please see http://library.kumc.edu/authors-fund.xml.Leakage of the blood–brain barrier (BBB) is a common pathological feature in multiple sclerosis (MS). Following a breach of the BBB, albumin, the most abundant protein in plasma, gains access to CNS tissue where it is exposed to an inflammatory milieu and tissue damage, e.g., demyelination. Once in the CNS, albumin can participate in protective mechanisms. For example, due to its high concentration and molecular properties, albumin becomes a target for oxidation and nitration reactions. Furthermore, albumin binds metals and heme thereby limiting their ability to produce reactive oxygen and reactive nitrogen species. Albumin also has the potential to worsen disease. Similar to pathogenic processes that occur during epilepsy, extravasated albumin could induce the expression of proinflammatory cytokines and affect the ability of astrocytes to maintain potassium homeostasis thereby possibly making neurons more vulnerable to glutamate exicitotoxicity, which is thought to be a pathogenic mechanism in MS. The albumin quotient, albumin in cerebrospinal fluid (CSF)/albumin in serum, is used as a measure of blood-CSF barrier dysfunction in MS, but it may be inaccurate since albumin levels in the CSF can be influenced by multiple factors including: 1) albumin becomes proteolytically cleaved during disease, 2) extravasated albumin is taken up by macrophages, microglia, and astrocytes, and 3) the location of BBB damage affects the entry of extravasated albumin into ventricular CSF. A discussion of the roles that albumin performs during MS is put forth

Reproducibility of pharmacological ASL using sequences from different vendors: implications for multicenter drug studies

The current study assesses the multicenter feasibility of pharmacological arterial spin labeling (ASL) by comparing a caffeine-induced relative cerebral blood flow decrease (%CBF↓) measured with two pseudo-continuous ASL sequences as provided by two major vendors. Twenty-two healthy volunteers were scanned twice with both a 3D spiral (GE) and a 2D EPI (Philips) sequence. The inter-session reproducibility was evaluated by comparisons of the mean and within-subject coefficient of variability (wsCV) of the %CBF↓, both for the total cerebral gray matter and on a voxel level. The %CBF↓ was larger when measured with the 3D spiral sequence (23.9 ± 5.9 %) than when measured with the 2D EPI sequence (19.2 ± 5.6 %) on a total gray matter level (p = 0.02), and on a voxel level in the posterior watershed area (p < 0.001). There was no difference between the gray matter wsCV of the 3D spiral (57.3 %) and 2D EPI sequence (66.7 %, p = 0.3), whereas on a voxel level, the wsCV was visibly different between the sequences. The observed differences between ASL sequences of both vendors can be explained by differences in the employed readout modules. These differences may seriously hamper multicenter pharmacological ASL, which strongly encourages standardization of ASL implementation